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Pr efACe
Since my undergraduate years in psychology, I’ve been fascinated by how 
psychoactive substances produce behavioral effects. This interest led to a 
career in psychopharmacology research that included many graduate and 
postdoctoral years studying lab rats in Skinner boxes and mazes. Once I be-
gan teaching undergraduates at a university, I found that my students were 
also curious about how drugs altered behavior. Students wondered not only 
about the physiological impacts of college drug use but also about how med-
icines can treat psychological disorders such as depression and schizophre-
nia. But of particular interest were the effects of psychoactive drugs on the 
brain. This introductory textbook developed from my efforts to address 
these interests.
An Introduction to Drugs and the Neuroscience of Behavior offers an in-
troduction to the field of psychopharmacology from the perspective of how 
drug actions in the brain affect psychological processes. The text approaches 
this rapidly advancing field by providing an introduction to major topics in 
psychopharmacology. I kept in mind that students have different backgrounds 
in neuroscience. Therefore, Chapter 2 provides an introductory overview of 
the nervous system, and Chapter 3 provides a basic coverage of neurotrans-
mission.
Chapter 4 provides an overview of pharmacology principles, covering im-
portant drug properties that are necessary for understanding psychoactive 
drug actions and effects. By mastering these chapters on the nervous system 
and pharmacology, students will possess a sufficient background to compre-
hend subsequent chapters on psychoactive drugs.
In addition to the major drug classes in psychopharmacology, this book 
addresses newer drugs and recent trends in drug use. For example, the current 
edition includes information on bath salts, energy drinks, modern tobacco 
products such as tobacco orbs, medicinal marijuana, synthetic marijuana, and 
antidepressant drug use for treating anxiety.
How the Materials Are Organized
During the development of this textbook, I carefully attended to how this mate-
rial is delivered to an undergraduate audience. My approach consists of a care-
ful, step-by-step presentation of information supplemented by illustrations, 
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figures, boxes, and several unique pedagogical features. These features in-
clude the following.
from Ac tions  to  ef fec ts
Each chapter ends with a section called “From Actions to Effects.” These sec-
tions cover a topic that brings together information presented in the chapter, 
providing a way to assemble multiple topics for addressing a single concept. 
In particular, these topics focus on a concept that requires understanding a 
drug’s actions to account for its effects. These sections aid in the conceptual 
understanding of chapter material.
stop & Check
Stop & Check questions conclude each section in each chapter. These ques-
tions allow students to self-assess their understanding of main points covered 
in the previous section.
review!
Chapters include important reminders of facts or concepts covered in previous 
chapters. This helps integrate the diverse material covered in this text.
research techniques  and methods
Chapters include boxes that cover a research technique or method used in 
psychopharmacology research. These boxes model good working science and 
provide an easy reference when students come across research findings de-
rived from each technique. These studies are also important in fostering criti-
cal thinking habits in students.
Key terms
Each chapter ends with a list of key terms from the chapter. A definition is pro-
vided for each key term in a combined glossary and index at the end of the book.
Visit www.cengagebrain.com to access the free companion Web site for 
this text, which includes a glossary, flash cards, quizzes, and more.
supplementar y  materials
The text comes equipped with PowerPoint presentations and a test bank of 
exam questions organized by chapter, provided by Renee Haskew-Layton 
at Chimborazo Publishing, Inc. Access these supplements on the companion 
Web site at www.cengagebrain.com.
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